146 related articles for article (PubMed ID: 35367578)
1. p53 mutants G245S and R337H associated with the Li-Fraumeni syndrome regulate distinct metabolic pathways.
Meneghetti BV; Wilson R; Dias CK; Cadore NA; Klamt F; Zaha A; Ferreira HB; Monteiro KM
Biochimie; 2022 Jul; 198():141-154. PubMed ID: 35367578
[TBL] [Abstract][Full Text] [Related]
2. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
3. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
[TBL] [Abstract][Full Text] [Related]
4. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
[TBL] [Abstract][Full Text] [Related]
5. TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient.
Giacomazzi J; Selistre S; Duarte J; Ribeiro JP; Vieira PJ; de Souza Macedo G; Rossi C; Czepielewski M; Netto CB; Hainaut P; Ashton-Prolla P
BMC Cancer; 2013 Apr; 13():187. PubMed ID: 23570263
[TBL] [Abstract][Full Text] [Related]
6. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.
Macedo GS; Vieira IA; Vianna FSL; Alemar B; Giacomazzi J; Brandalize APC; Caleffi M; Volc SM; de Campos Reis Galvão H; Palmero EI; Achatz MI; Ashton-Prolla P
Fam Cancer; 2018 Apr; 17(2):269-274. PubMed ID: 28756477
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of two novel germ line p53 mutations in the non-LFS/non-LFL breast cancer families in Chinese population.
Cao AY; Jin W; Shi PC; Di GH; Shen ZZ; Shao ZM
Breast Cancer Res Treat; 2010 Jan; 119(2):295-303. PubMed ID: 19238535
[TBL] [Abstract][Full Text] [Related]
8. Pediatric cancer and Li-Fraumeni/Li-Fraumeni-like syndromes: a review for the pediatrician.
Giacomazzi CR; Giacomazzi J; Netto CB; Santos-Silva P; Selistre SG; Maia AL; Oliveira VZ; Camey SA; Goldim JR; Ashton-Prolla P
Rev Assoc Med Bras (1992); 2015; 61(3):282-9. PubMed ID: 26248253
[TBL] [Abstract][Full Text] [Related]
9. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
10. Frequency of Thyroid Carcinoma in Brazilian TP53 p.R337H Carriers With Li Fraumeni Syndrome.
Formiga MNDC; de Andrade KC; Kowalski LP; Achatz MI
JAMA Oncol; 2017 Oct; 3(10):1400-1402. PubMed ID: 28114597
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Li-Fraumeni syndrome and Li-Fraumeni-like families for germline mutations in Bcl10.
Stone JG; Eeles RA; Sodha N; Murday V; Sheriden E; Houlston RS
Cancer Lett; 1999 Dec; 147(1-2):181-5. PubMed ID: 10660104
[TBL] [Abstract][Full Text] [Related]
12. The Common Germline
Jeffers JR; Pinto EM; Rehg JE; Clay MR; Wang J; Neale G; Heath RJ; Lozano G; Lalli E; Figueiredo BC; Pappo AS; Rodriguez-Galindo C; Chen W; Pounds S; Ribeiro RC; Zambetti GP
Cancer Res; 2021 May; 81(9):2442-2456. PubMed ID: 33637564
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
Matzenbacher Bittar C; de Araújo Rocha YM; Vieira IA; Rosset C; Andreis TF; Sartor ITS; Artigalás O; Netto CBO; Alemar B; Macedo GS; Ashton-Prolla P
PLoS One; 2021; 16(9):e0251639. PubMed ID: 34529667
[TBL] [Abstract][Full Text] [Related]
14. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
[TBL] [Abstract][Full Text] [Related]
15. Association Between the Oligomeric Status of p53 and Clinical Outcomes in Li-Fraumeni Syndrome.
Fischer NW; Prodeus A; Tran J; Malkin D; Gariépy J
J Natl Cancer Inst; 2018 Dec; 110(12):1418-1421. PubMed ID: 29955864
[TBL] [Abstract][Full Text] [Related]
16. Identification of the
Sandoval RL; Masotti C; de Macedo MP; Ribeiro MFSA; Leite ACR; Meireles SI; Bovolin RM; Santini FC; Munhoz RR; Jardim DLF; Katz A; Camargo AA; Fernandes GDS; Achatz MI
JCO Glob Oncol; 2021 Jul; 7():1141-1150. PubMed ID: 34270331
[TBL] [Abstract][Full Text] [Related]
17. Reducing Fatty Acid Oxidation Improves Cancer-free Survival in a Mouse Model of Li-Fraumeni Syndrome.
Wang PY; Ma J; Li J; Starost MF; Wolfgang MJ; Singh K; Pirooznia M; Kang JG; Hwang PM
Cancer Prev Res (Phila); 2021 Jan; 14(1):31-40. PubMed ID: 32958587
[TBL] [Abstract][Full Text] [Related]
18. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.
Kamihara J; Rana HQ; Garber JE
Hum Mutat; 2014 Jun; 35(6):654-62. PubMed ID: 24706533
[TBL] [Abstract][Full Text] [Related]
19. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage.
Zerdoumi Y; Lanos R; Raad S; Flaman JM; Bougeard G; Frebourg T; Tournier I
Hum Mol Genet; 2017 Jul; 26(14):2591-2602. PubMed ID: 28369373
[TBL] [Abstract][Full Text] [Related]
20.
da Silva PFF; Goveia RM; Teixeira TB; Gamba BF; de Lima AP; Rogatto SR; Silveira-Lacerda EP
Biomolecules; 2022 Apr; 12(5):. PubMed ID: 35625568
[No Abstract] [Full Text] [Related]
[Next] [New Search]
